STP13 Antibody

Overview of ST13 Protein and Antibody Targets

ST13 (Hsp70-interacting protein, HIP) facilitates HSP70 and HSP90 interactions during glucocorticoid receptor maturation . It is implicated as a tumor suppressor, with reduced expression observed in colorectal carcinomas . Two primary commercial antibodies target human ST13:

Cancer Biology

ST13 antibodies are used to study its tumor-suppressive role. Reduced ST13 levels correlate with colorectal cancer progression, suggesting its utility as a diagnostic biomarker .

Protein Interaction Studies

ST13 antibodies enable detection of its interactions with HSP70/HSP90 complexes, critical for glucocorticoid receptor assembly .

Monoclonal Antibody STP13 Against Salmonella typhi

A separate monoclonal antibody named STP13 (immunoglobulin G2a subclass) targets a 34 kDa protein antigen of S. typhi. Key features include:

• Specificity: Detects S. typhi but not other enteric pathogens (e.g., E. coli, Yersinia) .

• Diagnostic Use: Detects bacterial antigens in bodily fluids at 0.6 µg/ml sensitivity .

Key Findings from ST13 Antibody Studies

• Proteintech’s 26581-1-AP validates ST13 expression in colorectal epithelia and adenocarcinoma cells .

• Prospec’s PAT1F1AT confirms reduced ST13 levels in primary tumors compared to adjacent healthy tissue .

• STP13 (anti-Salmonella) enables specific detection of typhoid fever antigens in clinical samples .